Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APIDULCIS: Apixaban vs Stopping Anticoagulation in VTE
NCT03678506Phase 4Terminated
- Sponsor
- Fondazione Arianna Anticoagulazione
- Start
- Aug 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Fondazione Arianna Anticoagulazione. Primary endpoints: Number and rate of patients with confirmed recurrent VTE and VTE-related death at 18 months and Number and rate of major Bleeding events at 18 months. Started Aug 2018; status: terminated.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03678506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678506.